BELL.L

Belluscura Plc
Belluscura PLC - Notice of AGM
2nd August 2024, 06:00
TwitterFacebookLinkedIn
To continue viewing RNS, please confirm that you are a Private Investor*

* A Private Investor is a recipient of the information who meets all of the conditions set out below, the recipient:

  1. Obtains access to the information in a personal capacity;
  2. Is not required to be regulated or supervised by a body concerned with the regulation or supervision of investment or financial services;
  3. Is not currently registered or qualified as a professional securities trader or investment adviser with any national or state exchange, regulatory authority, professional association or recognised professional body;
  4. Does not currently act in any capacity as an investment adviser, whether or not they have at some time been qualified to do so;
  5. Uses the information solely in relation to the management of their personal funds and not as a trader to the public or for the investment of corporate funds;
  6. Does not distribute, republish or otherwise provide any information or derived works to any third party in any manner or use or process information or derived works for any commercial purposes.
RNS Number : 8752Y
Belluscura PLC
02 August 2024
 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

Belluscura plc

("Belluscura" or the "Company" or "Group")

 

 Notice of AGM

 

LONDON, U.K. AND PLANO, TX, U.S. (2 August 2024). Belluscura plc (AIM:BELL), announces that the Notice of Annual General Meeting ("AGM"), to be held at 12.00 p.m on Tuesday 27 August 2024, is being posted to shareholders and will shortly be available on the Company's website at: https://investors.belluscura.com/investors/shareholder-information.

 

The Annual Report and Accounts for the year ended 31 December 2023 is available on the Company's website at: https://www.belluscura.com/financials/annual-and-interim-reports/

 

If you wish to submit a proxy vote for this meeting, please submit your vote online at www.signalshares.com. For your vote to be valid please ensure that it is received by no later than 12.00 p.m. on 25 August 2024. Alternatively, should you wish to vote via the CREST system, please see the instructions in the Notice of Meeting.

 

 

 

For further information please contact:

Belluscura plc

Tel: +44 (0)20 3128 8100

Adam Reynolds, Chairman
Robert Rauker, Chief Executive Officer
Simon Neicheril, Chief Financial Officer




SPARK Advisory Partners Limited

Nominated Adviser

Tel: +44 (0)20 3368 3550

Neil Baldwin / Jade Bayat




Dowgate Capital Limited

Broker

Tel: +44 (0)20 3903 7715

James Serjeant / Russell Cook




MHP

Financial PR & Investor Relations

Tel: +44 (0)20 3128 8100

email: Belluscura@mhpgroup.com

Katie Hunt/Matthew Taylor



 

 

 

About Belluscura plc (www.belluscura.com)

Belluscura is a UK medical device company focused on developing oxygen enrichment technology spanning broad industries and therapies. Our innovative oxygen technologies are designed with a global purpose: to create improved health and economic outcomes for the patients, healthcare providers and insurance organisations. 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOAFZGGRKMDGDZM]]>
TwitterFacebookLinkedIn